logo-loader

Algernon Pharmaceuticals closes special warrants offering that raised nearly C$7M

Published: 12:55 13 May 2020 EDT

algernon
The money will be used for ongoing research, clinical trials, working capital and general corporate purposes

Algernon Pharmaceuticals Inc (CSE: AGN) (OTCQB:AGNPF) announced Wednesday it closed a private placement offering of special warrants that raised nearly C$7 million. 

The Vancouver-based firm issued 19,605,285 special warrants for $0.35 each and upsized the offering from an initial $5 million target. Gross proceeds totaled $6,861,849.

The money will be used for ongoing research, clinical trials, working capital and general corporate purposes.

READ: Algernon Pharmaceuticals receives first ethics approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Each special warrant consists of one common share and one common share purchase warrant, the latter entitling its holder to another common share at an exercise price of $0.55 for a period of two years.

Algernon, based in Vancouver, is a drug repurposing company that investigates safe, already approved drugs for new disease applications. The company has filed new intellectual property rights around the world for Ifenprodil for the treatment of respiratory diseases and is working to develop a proprietary injectible, slow-release formulation.

In coronavirus (COVID-19) patients, the company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can each release glutamate and cytokines, respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

Algernon has received Health Canada approval to proceed with Phase 2b/3 of a multinational study looking at Ifenprodil, which could be used in the treatment of COVID-19.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham 

 

Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was initially developed to...

20 hours, 36 minutes ago